Individual genomes instead of race for personalized medicine

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 3, 2008, Pages 306-309

  Ng, P C ^a   Zhao, Q ^a   Levy, S ^a   Strausberg, R L ^a   Venter, J C ^a  

^a J CRAIG VENTER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; SULFONYLUREA DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ALLELE; BLEEDING; CYP2C9 GENE; CYP2D6 GENE; DRUG METABOLISM; ENVIRONMENTAL FACTOR; ENZYME SUBSTRATE COMPLEX; FOUNDER EFFECT; GENE; GENE SEQUENCE; GENETIC DIFFERENCE; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; GENOME; GENOTYPE; HEART DISEASE; HEREDITY; HUMAN; NOTE; PRIORITY JOURNAL; RACE; RACE DIFFERENCE; SEQUENCE ANALYSIS;

ANTICOAGULANTS; ETHNIC GROUPS; GENETIC PRIVACY; GENETIC SCREENING; HUMANS; MALE; PHARMACOGENETICS; WARFARIN;

EID: 49949096143     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.114     Document Type: Note

References (17)

1. Lazarou, J., Pomeranz, B.H. & Corey, P.N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
2. Flockhart, D.A. & McMillin G. A Pharmacogenomics Approach to Using Warfarin. ARUP Laboratories, Salt Lake City, UT 〈http://arup.cnpg.com/med/ webinar/flockhartmcmillin/20060829〉 (2006).
3. Evans, W.E. & Relling, M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
4. Xie, H.G., Kim, R.B., Wood, A.J. & Stein, C.M. Molecular basis of ethnic differences in drug disposition and response. Annu. Rev. Pharmacol. Toxicol. 41, 815-850 (2001).
5. Duster, T. Medicalisation of race. Lancet 369, 702-704 (2007).
6. Kaiser, J. Breakthrough of the year: it's all about me. Science 318, 1843 (2007).
7. Wheeler, D.A. et al. The complete genome of an individual by massively parallel DNA sequencing. Nature 452, 872-876 (2008).
8. Levy, S. et al. The diploid genome sequence of an individual human. PLoS Biol. 5, e254 (2007).
9. Ingelman-Sundberg, M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J. 5, 6-13 (2005).
10. Broad Institute Center for Genotyping and Analysis. Projected pricing (March 2008) 〈http://www.broad.mit.edu/gen_analysis/genotyping/pricing. html〉.
11. McGuire, A.L., Caulfield, T. & Cho, M.K. Research ethics and the challenge of whole-genome sequencing. Nat. Rev. Genet. 9, 152-156 (2008).
12. Cox, E., Mager, D. & Weisbart, E. Geographic Variation Trends in Prescription Use: 2000 to 2006. 23 (Express Scripts, St. Louis, MO, 2008).
13. Evelyn, B. et al. Participation of racial/ethnic groups in clinical trials and race-related labeling: a review of new molecular entities approved 1995-1999. J. Natl. Med. Assoc. 93, 18S-24S (2001).
14. Mak, W.W., Law, R.W., Alvidrez, J. & Perez-Stable, E.J. Gender and ethnic diversity in NIMH-funded clinical trials: review of a decade of published research. Adm. Policy Ment. Health 34, 497-503 (2007).
15. Seguin, B., Hardy, B., Singer, P.A. & Daar, A.S. Bidil: recontextualizing the race debate. Pharmacogenomics J. 8, 169-173 (2008).
16. U.S. Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels 〈http://www.fda.gov/cder/genomics/ genomic_biomarkers_table.htm〉 (updated 7 April 2008).
17. Hernandez-Boussard, T. et al. The pharmacogenetics and pharmacogenomics knowledge base: accentuating the knowledge. Nucleic Acids Res. 36, D913-D918 (2008).